In people with obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg resulted in 20% reduction in major adverse cardiovascular events [(MACE), death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke] compared to placebo (SELECT trial) after a mean follow-up of 39.8 months this is the first trial demonstrating cardiovascular benefit for an obesity pharmacotherapy [110]
This fusion of cutting-edge medication and modern healthcare delivery are empowering people to achieve their weight loss goals from the comfort and privacy of their homes
Ferroptosis occurs during ovarian aging
Both LEVs and SEVs demonstrated a superior whitening impact on melanoma cells when compared to arbutin, a frequently used positive control, with LEVs being particularly effective
Choosing patience over quick fixes protects not just your skin, but your long-term health
Kang AM, Padilla-Jones A, Fisher ES, Akakpo JY, Jaeschke H, Rumack BH, Gerkin RD, Curry SC